Polymorphisms in BRCA1, BRCA1-interacting Genes and Susceptibility of Breast Cancer in Chinese Women

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2009 Jun 2

PMID 19484476

Citations 16

Authors

Xiang Huo

Cheng Lu

Xinen Huang

Zhibin Hu

Guangfu Jin

Hongxia Ma

Xuechen Wang

Jianwei Qin

Xinru Wang

Hongbing Shen

Jinhai Tang

Affiliations

Soon will be listed here.

Abstract

Purpose: BRCA1-interacting protein C-terminal helicase 1 (BRIP1) and zinc finger protein 350 (ZNF350) work with BRCA1 in tumor suppression procedures. Low penetrance variants of these three genes may jointly affect individuals' breast cancer susceptibility in general population.

Methods: We focused on potentially functional single nucleotide polymorphisms (SNPs) in the coding regions of BRIP1, ZNF350 and BRCA1 and pairwise-tagging approach was used to minimize the number of SNPs. Five SNPs were selected and genotyped by PCR-restriction fraction length polymorphism or PCR-primer introduced restriction analysis assays in a case-control study with 568 breast cancer cases and 624 controls in a Chinese population.

Results: All of the five SNPs except rs2278415 of ZNF350 conferred a modestly increased risk, although, with no statistical significance. Joint effect analyses indicated that all the variant genotypes of ZNF350 polymorphisms accounted for increased breast cancer risk among subjects carrying variant homozygote of BRCA1 rs799917, particularly for ZNF350 rs4986773 (OR = 2.03, 95%CI = 1.02-4.05, the test for gene-gene interaction P (int) = 0.059).

Conclusion: BRCA1 and ZNF350 may jointly contribute to individuals' susceptibility of breast cancer in Chinese women. Further functional studies are warranted to validate our findings.

Citing Articles

Genetic interactions effects for cancer disease identification using computational models: a review.

Manavalan R, Priya S Med Biol Eng Comput. 2021; 59(4):733-758.

PMID: 33839998 DOI: 10.1007/s11517-021-02343-9.

Two tSNPs in BRIP1 are associated with breast cancer during TDT analysis.

Li X, Li Z, Yang M, Luo Y, Hu L, Xiao Z Mol Genet Genomic Med. 2021; 9(2):e1578.

PMID: 33403820 PMC: 8077123. DOI: 10.1002/mgg3.1578.

Screening of BRCA1 variants c.190T>C, 1307delT, g.5331G>A and c.2612C>T in breast cancer patients from North India.

Kour A, Sambyal V, Guleria K, Singh N, Uppal M, Manjari M Genet Mol Biol. 2020; 43(2):e20190014.

PMID: 32453341 PMC: 7250277. DOI: 10.1590/1678-4685-GMB-2019-0014.

Association between BRCA1 polymorphisms rs799917 and rs1799966 and breast cancer risk: a meta-analysis.

Yang M, Du X, Zhang F, Yuan S J Int Med Res. 2019; 47(4):1409-1416.

PMID: 30832521 PMC: 6460623. DOI: 10.1177/0300060519826819.

Novel Associations between BRCA1 Variants C.181 T>G (Rs28897672) and Ovarian Crisk in Saudi Females.

Alyahri N, Abdi S, Khan W, Elrobh M, Addar M, Babay Z J Med Biochem. 2019; 38(1):13-21.

PMID: 30820179 PMC: 6298454. DOI: 10.2478/jomb-2018-0037.

References

Rutter J, Smith A, Davila M, Sigurdson A, Giusti R, Pineda M . Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Hum Mutat. 2003; 22(2):121-8. DOI: 10.1002/humu.10238. View

Garcia V, Dominguez G, Garcia J, Silva J, Pena C, Silva J . Altered expression of the ZBRK1 gene in human breast carcinomas. J Pathol. 2004; 202(2):224-32. DOI: 10.1002/path.1513. View

Vahteristo P, Yliannala K, Tamminen A, Eerola H, Blomqvist C, Nevanlinna H . BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer. 2006; 6:19. PMC: 1368988. DOI: 10.1186/1471-2407-6-19. View

Soucek P, Borovanova T, Pohlreich P, Kleibl Z, Novotny J . Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study. Breast Cancer Res Treat. 2006; 103(2):219-24. DOI: 10.1007/s10549-006-9367-9. View

Furuta S, Wang J, Wei S, Jeng Y, Jiang X, Gu B . Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature. Cancer Cell. 2006; 10(1):13-24. DOI: 10.1016/j.ccr.2006.05.022. View

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

Hahn L, Ritchie M, Moore J . Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003; 19(3):376-82. DOI: 10.1093/bioinformatics/btf869. View

Zheng L, Pan H, Li S, Flesken-Nikitin A, Chen P, Boyer T . Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell. 2000; 6(4):757-68. DOI: 10.1016/s1097-2765(00)00075-7. View

Freedman M, Penney K, Stram D, Riley S, McKean-Cowdin R, Le Marchand L . A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk. Cancer Res. 2005; 65(16):7516-22. DOI: 10.1158/0008-5472.CAN-05-0132. View

10.

Ford D, Easton D, Peto J . Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995; 57(6):1457-62. PMC: 1801430. View

11.

Onay V, Briollais L, Knight J, Shi E, Wang Y, Wells S . SNP-SNP interactions in breast cancer susceptibility. BMC Cancer. 2006; 6:114. PMC: 1522021. DOI: 10.1186/1471-2407-6-114. View

12.

Garcia-Closas M, Egan K, Newcomb P, Brinton L, Titus-Ernstoff L, Chanock S . Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet. 2006; 119(4):376-88. DOI: 10.1007/s00439-006-0135-z. View

13.

Sauna Z, Kimchi-Sarfaty C, Ambudkar S, Gottesman M . Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007; 67(20):9609-12. DOI: 10.1158/0008-5472.CAN-07-2377. View

14.

Dunning A, Chiano M, Smith N, Dearden J, Gore M, Oakes S . Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet. 1997; 6(2):285-9. DOI: 10.1093/hmg/6.2.285. View

15.

Huo X, Hu Z, Zhai X, Wang Y, Wang S, Wang X . Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis. Breast Cancer Res Treat. 2006; 102(3):329-37. DOI: 10.1007/s10549-006-9332-7. View

16.

Eelen G, Vanden Bempt I, Verlinden L, Drijkoningen M, Smeets A, Neven P . Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy. Oncogene. 2008; 27(30):4233-41. DOI: 10.1038/onc.2008.51. View

17.

Yun J, Lee W . Degradation of transcription repressor ZBRK1 through the ubiquitin-proteasome pathway relieves repression of Gadd45a upon DNA damage. Mol Cell Biol. 2003; 23(20):7305-14. PMC: 230312. DOI: 10.1128/MCB.23.20.7305-7314.2003. View

18.

Sigurdson A, Hauptmann M, Chatterjee N, Alexander B, Doody M, Rutter J . Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer. 2004; 4:9. PMC: 408462. DOI: 10.1186/1471-2407-4-9. View

19.

Bhatti P, Church D, Rutter J, Struewing J, Sigurdson A . Candidate single nucleotide polymorphism selection using publicly available tools: a guide for epidemiologists. Am J Epidemiol. 2006; 164(8):794-804. DOI: 10.1093/aje/kwj269. View

20.

Struewing J, Hartge P, Wacholder S, Baker S, Berlin M, McAdams M . The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997; 336(20):1401-8. DOI: 10.1056/NEJM199705153362001. View